Processing...
All Trials
Search
Search
There are 1659 active trials in our database.
Click on a trial to see more information.
1659 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Monotherapy ALE.P03, a Claudin‑1–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload, for adults with centrally confirmed CLDN1-positive advanced/metastatic solid tumors limited to mCRC, intrahepatic cholangiocarcinoma, squamous NSCLC, urothelial carcinoma, or cervical squamous cell carcinoma. Requires RECIST-measurable, ECOG 0–1 disease with prior standard therapy (dose escalation: refractory/intolerant to all; expansion/phase II: 1–2 prior lines and prior targeted therapy if actionable drivers), excluding active CNS metastases and significant ILD/pneumonitis.
ClinicalTrials.gov ID: NCT07169734
TrialFetch AI summary: Adults with advanced/metastatic solid tumors who have exhausted standard options receive IV TJ101, a bispecific EGFR/B7-H3 antibody–drug conjugate, every 3 weeks in dose escalation with biomarker-driven expansion cohorts. Excludes prior topoisomerase I inhibitor or TOP1i-ADC exposure, active ILD/pneumonitis, significant ocular or uncontrolled cardiovascular disease, and active CNS disease unless treated and stable.
ClinicalTrials.gov ID: NCT07181473
TrialFetch AI summary: Adults with advanced/metastatic colorectal adenocarcinoma, NSCLC, or pancreatic ductal adenocarcinoma after at least one prior systemic therapy receive IV PHN-012, a first-in-human investigational antibody–drug conjugate (target undisclosed; exclusion suggests possible topoisomerase‑I payload). Open-label dose escalation with tumor-specific expansion; requires measurable disease, ECOG 0–1, adequate organs, and available tissue; excludes prior topo‑I ADCs, unstable CNS mets, and active/past ILD/pneumonitis.
ClinicalTrials.gov ID: NCT07127874
TrialFetch AI summary: Adults with metastatic or unresectable clear cell RCC that is CD70-positive (≥10% by IHC) after progression on at least one ICI and one TKI receive lymphodepletion (fludarabine/cyclophosphamide) followed by a single infusion of allogeneic umbilical cord blood–derived NK cells engineered with a CD70-directed CAR and IL-15, with CRISPR knockout of TGF-β receptor type II to resist TGF-β–mediated immunosuppression. Key exclusions include active infections, autoimmune disease requiring treatment, uncontrolled CNS disease, and significant organ comorbidities.
ClinicalTrials.gov ID: NCT07072234
TrialFetch AI summary: Adults with advanced/metastatic MUC1-overexpressing solid tumors: dose-escalation/expansion of M0324, an investigational MUC1-conditional CD40 agonist antibody, as monotherapy (post–standard therapy) or combined with pembrolizumab after prior ICI progression; separate cohort tests M0324 plus mFOLFIRINOX as first-line therapy for metastatic pancreatic ductal adenocarcinoma. Key exclusions include significant GI inflammation (e.g., chronic grade ≥2 diarrhea/IBD) and uncontrolled cardiovascular disease.
ClinicalTrials.gov ID: NCT07166601
TrialFetch AI summary: Adults with unresectable or metastatic hepatocellular carcinoma (ECOG 0–1, Child-Pugh A) receive ZW251, an investigational glypican‑3–targeted antibody–drug conjugate delivering a camptothecin-based topoisomerase I inhibitor. Single‑arm dose escalation and expansion assess safety, PK, and preliminary activity to determine a recommended dose.
ClinicalTrials.gov ID: NCT07164313
TrialFetch AI summary: Adults with homozygous MTAP-deleted solid tumors (ECOG 0–1) receive oral BAY 3713372, an MTAP-selective, second-generation PRMT5 inhibitor exploiting synthetic lethality, with monotherapy dose escalation and expansions in all MTAP-deleted tumors plus focused cohorts in NSCLC and PDAC. Expansion includes BAY 3713372 alone and in combinations for NSCLC and PDAC; key cardiac comorbidities are excluded.
ClinicalTrials.gov ID: NCT06914128
TrialFetch AI summary: Adults with FRα-positive metastatic/recurrent lung adenocarcinoma and malignant pleural effusion (ECOG 0–1, prior systemic therapy) receive cyclophosphamide/fludarabine lymphodepletion followed by a single intrapleural infusion of autologous MOv19-BBz CAR T cells targeting folate receptor‑alpha (second‑generation CAR with 4‑1BB/CD3ζ). Candidates must be eligible for standard checkpoint inhibitors (which may start ≥28 days post‑CAR T) and have controlled CNS disease; key exclusions include extensive parenchymal lung involvement beyond one lobe, significant undrainable effusion, ILD/pneumonitis, active hepatitis, and autoimmune disease requiring immunosuppression.
ClinicalTrials.gov ID: NCT07116057
TrialFetch AI summary: Enrolling adult men with progressive mCRPC (ECOG 0–1) after ≥1 ARPI and either prior taxane or appropriate to defer taxane, requiring PSMA-avid disease on PSMA-PET and adequate organ function; includes both 177Lu-PSMA–naïve and –experienced cohorts. Patients receive AB001 (212Pb‑NG001), a PSMA-targeted alpha radioligand delivering short–path length high-LET radiation via 212Pb decay, given IV every 6 weeks for up to 4–6 cycles with dose/schedule optimization based on safety and preliminary activity.
ClinicalTrials.gov ID: NCT07214961
TrialFetch AI summary: Adults with previously treated, locally advanced/metastatic small cell lung cancer or other neuroendocrine tumors (e.g., LCNEC, NEPC, high‑grade GI‑NET, Merkel cell) receive BL‑M14D1, an investigational DLL3‑targeted antibody–drug conjugate with a topoisomerase I inhibitor payload, given IV every 21 days. Suitable for ECOG 0–1 patients post‑standard therapy (SCLC requires prior platinum); excludes prior topo‑I ADCs, significant cardiac/QTc issues, ILD/pneumonitis, active CNS disease, and uncontrolled infections.
ClinicalTrials.gov ID: NCT07080242